CONTEXT AND OBJECTIVE: Noninvasive strategies for evaluating non-alcoholic fatty liver disease (NAFLD) have been investigated over the last few decades. Our aim was to evaluate the diagnostic accuracy of a new hepatic ultrasound score for NAFLD in the ELSA-Brasil study. DESIGN AND SETTINGS: Diagnostic accuracy study conducted in the ELSA center, in the hospital of a public university. METHODS: Among the 15,105 participants of the ELSA study who were evaluated for NAFLD, 195 individuals were included in this sub-study. Hepatic ultrasound was performed (deep beam attenuation, hepatorenal index and anteroposterior diameter of the right hepatic lobe) and compared with the hepatic steatosis findings from 64-channel high-resolution computed tomography (CT). We also evaluated two clinical indices relating to NAFLD: the fatty liver index (FLI) and the hepatic steatosis index (HSI). RESULTS: Among the 195 participants, the NAFLD frequency was 34.4%. High body mass index, high waist circumference, diabetes and hypertriglyceridemia were associated with high hepatic attenuation and large anteroposterior diameter of the right hepatic lobe, but not with the hepatorenal index. The hepatic ultrasound score, based on hepatic attenuation and the anteroposterior diameter of the right hepatic lobe, presented the best performance for NAFLD screening at the cutoff point 
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of conditions ranging from hepatic steatosis to fibrosis 1 and has also been associated with endothelial dysfunction, 2 metabolic syndrome, 3 insulin resistance, 4 type 2 diabetes, 5 dyslipidemia, 5 and independent cardiovascular events. [6] [7] [8] Liver biopsy is considered to be the gold standard for diagnosing and staging NAFLD. 1 However, its use is limited by cost, sampling error and adverse events. Furthermore, liver biopsy is not feasible for populationbased studies and cohort studies.
Interest in noninvasive imaging strategies for NAFLD screening, including conventional B-mode ultrasound, has increased significantly over the last decade. [9] [10] [11] [12] [13] [14] Although computed tomography (CT) and magnetic resonance imaging (MRI) are superior to conventional B-mode ultrasound for detecting fatty liver infiltration, their costs and adverse effects limit their usefulness in clinical practice, field surveys, epidemiological studies and clinical trials. [11] [12] [13] [14] [15] [16] [17] [18] The positive aspects of B-mode ultrasound, such as being routinely available and completely safe, make it a valuable tool in clinical settings and large population studies. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The most common B-mode ultrasound criteria reported for diffuse hepatic fatty infiltration are as follows: (1) parenchymal brightness; (2) deep-beam attenuation; (3) vascular blurring (loss of echoes from the walls of the portal veins); and (4) increasing discrepancy of echogenicity between the liver and kidney parenchyma (hepatorenal index). 1, 10, 15, [19] [20] [21] [22] Among these criteria, deep-beam attenuation has presented better performance for diagnosing fatty liver disease. [25] [26] [27] [28] [29] [30] [31] However, conventional B-mode ultrasonography presents limitations, including subjective evaluation and operator dependency. Therefore, inclusion of a new biometric parameter, i.e. measurement of the anteroposterior diameter of the right hepatic lobe, was proposed in a Brazilian cohort of 15, 105 civil servants aged 35 to 74 years in a study that was designed to evaluate the risk factors for diabetes and cardiovascular diseases: the Longitudinal Study for Adult Health (in Portuguese, "Estudo Longitudinal de Saúde do Adulto", known as ELSABrasil). [32] [33] [34] [35] The rationale behind using the anteroposterior diameter of the right hepatic lobe was the significant association with hepatic steatosis, confirmed by liver biopsy, that had previously been described.
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OBJECTIVE
Thus, the purpose of this study was to evaluate the diagnostic accuracy of a new hepatic ultrasound score for assessing NAFLD based on B-mode ultrasound deep-beam attenuation, the anteroposterior diameter of the right hepatic lobe and the hepatorenal index, compared with 64-channel multidetector CT findings (64-MDCT) in an ELSA-Brasil subsample.
The performance of 64-MDCT versus two clinical indices relating to NAFLD was also evaluated: the fatty liver index (FLI) 25 and the hepatic steatosis index (HSI).
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METHODS
Study design
This was a diagnostic accuracy study conducted on a subsample from the ELSA-Brasil study. 34 Full descriptions of the ELSA-Brasil study have been published elsewhere.
32-35
Sampling and settings
Our reference population was recruited at the ELSA-São Paulo site (n = 5,061 participants) and underwent liver ultrasound scanning one year before this sub-study, during the baseline visit. The ELSA-São Paulo site is located at the university hospital of the University of São Paulo (HU-USP), in the western area of the city of São Paulo, the largest metropolitan area in South America.
HU-USP was the only facility in this area of study, which includes 420,000 inhabitants.
For sampling purposes, participants who presented the following baseline characteristics were not included in this substudy: (1) self-reported alcohol intake above 40 g per day for men and 20 g per day for women; (2) self-reported liver disease; By taking the statistical power to be 80% and the prevalence of NAFLD to be 30%, based on the general population, 1 the sample size was estimated as 176 individuals.
In total, 195 participants were invited to participate in this sub-study and none were lost during the follow-up. On the same day on which they returned to HU-USP to participate in this substudy, they underwent new NAFLD biomarker testing, new liver ultrasound scanning and, lastly, an abdominal 64-MDCT scan to determine any presence of liver steatosis.
Written informed consent was obtained from all participants who agreed to participate in this study, and each subject received a copy of the consent form. The Internal Review Board of the University of São Paulo approved both the main study and this sub-study.
Furthermore, the recommendations of the Standards for
Reporting of Diagnostic Accuracy (STARD) for publication of accuracy studies were followed.
NAFLD biomarkers
For all of these 195 ELSA-Brasil participants, the fatty liver index (FLI) and the hepatic steatosis index (HIS) were applied as surrogate outcomes for hepatic steatosis, as described below: 35 Serum biochemistry parameters were evaluated using the enzymatic method (International Federation of Clinical Chemistry, IFCC; modified) performed on an Advia Siemens system for ALT and AST and the colorimetric kinetic method (Szasz) performed on the Advia Siemens system for GGT. 32 Liver tests were considered abnormal if they were at least one and half points above the upper limit of the normal reference values, as follows: ALT normal range: 10 to 35 IU/l for men and 10 to 31 IU/l for women; AST normal range: 9 to 43 IU/l for men and 9 to 36 IU/l for women; and GGT normal range: up to 30 IU/l for men and up to 24 IU/l for women. 34 Fasting glucose (hexoquinase) and serum triglycerides (glycerol phosphate peroxidase)
were also analyzed. Diabetes mellitus was defined as fasting glucose > 126 mg/dl or treatment with an anti-diabetic medication. 
19,20
The quality control for the ultrasound images obtained from the anteroposterior diameter measurement on the right hepatic lobe was based on the number of required anatomical landmarks in the axial ultrasound plane of the right hepatic lobe, as follows:
(1) unacceptable (no anatomical landmark); (2) 
Hepatic CT examination protocol
Imaging was performed using a Brilliance 64-MDCT scanner (Phillips, Bets, Netherlands). An enhanced 64-MDCT scan, which is a highly sensitive method for estimating hepatic fat, was performed to evaluate hepatic attenuation in Hounsfield units (HU).
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The indices applied in our inter-method comparison of fatty liver disease diagnoses were as follows: 2. Hepatic-splenic difference: The mean densities of the liver and spleen were calculated from the regions of interest.
The mean liver-to-spleen attenuation difference for each patient was determined by subtracting the mean splenic attenuation from the mean liver attenuation. Based on previous studies, a hepatic-splenic attenuation difference of more than 5 HU is an accurate predictor of the absence of significant macrovesicular steatosis (0%-5%), and a range from -10 to 5 HU is suggestive of mild to moderate steatosis (6%-30%); in our study, 5 HU was the cutoff point used for hepatic steatosis. 43 All examiners who performed ultrasound and CT exams were kept blinded with regard to the NAFLD diagnosis.
Statistics
The qqplot graphic and the Kolmogorov-Smirnov test were applied as normality tests to evaluate the distribution of continuous variables in our sample. the present sub-study, and they differentiated individuals with hepatic steatosis from those without hepatic steatosis, with good sensitivity (59% and 65%) and specificity (84.8% and 78.1%) for men and women, respectively.
Hepatic attenuation and the anteroposterior diameter of the right hepatic lobe, evaluated independently, were significantly associated (P < 0.001) with steatosis seen by means of 64-MDCT.
In contrast, no significant association was obtained when the hepatorenal index was evaluated by itself.
High BMI, high waist circumference and diagnoses of diabetes and hypertriglyceridemia were associated with increased hepatic deep-beam attenuation and increased anteroposterior diameter of the right hepatic lobe seen by means of B-mode ultrasound. However, only diabetes was positively associated with a hepatorenal index result suggestive of fatty liver.
Considering the low accuracy of the hepatorenal index for identifying individuals with hepatic steatosis, a hepatic ultrasound scoring system based exclusively on the following criteria was also explored: hepatic attenuation degree (mild: +1 point and moderate-severe: +2 points) and a cutoff for the anteropos- between the anteroposterior diameter of the right hepatic lobe and hepatic steatosis described previously. [26] [27] [28] [29] [30] 36 Moreover, these two B-mode ultrasound criteria were included in our ultrasound score to meet the requirement of selecting the most reliable, feasible and practical B-mode ultrasound parameters that could be evaluated on standardized images obtained at all site locations included in this longitudinal population study.
According to a meta-analysis conducted by Hernaez et al. 15 which included 49 studies that provided cross-tabulations of ultrasonography versus histology or standard imaging techniques, the overall sensitivity, specificity, positive likelihood ratio and negative likelihood ratio of ultrasound for detecting moderate-severe fatty liver were 84.8% (95% CI: 79.5-88.9), 93.6% meta-analysis, the ELSA-Brasil hepatic ultrasound score showed similar results for sensitivity and inferior results for specificity, which may be explained by the fact that only two ultrasound parameters were included in our analysis. In our study, the qualitative hepatorenal index assessment did not show any relationship with the clinical parameters associated with NAFLD, and it was not an accurate method for investigating hepatic steatosis, compared with 64-MDCT. However, it is important to note that in our study, the ultrasound evaluations on hepatic and renal parenchyma brightness did not use semi-quantitative methods (such as histogram echo intensity). According to previous studies, the hepatorenal index is an accurate method for quantifying fat infiltration in the liver, but mainly in populations without kidney diseases. 22 In fact, comparison between the kidney and liver parenchyma for detecting fat infiltration using ultrasound in a population-based study would be compromised because the prevalence of fatty kidney is not negligible and may be associated with cardiovascular risk factors.
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Figure 2. Receiver operator characteristic curve (ROC) for fatty liver index, hepatic steatosis index and ELSA ultrasound score for assessing non-alcoholic fatty liver disease (NAFLD), compared with hepatic steatosis diagnosis made using computed tomography (CT), on 195 ELSA-Brasil participants. In this sub-study on ELSA-Brasil, relatively high frequency of NAFLD was found: greater than 30% as assessed using 64-MDCT. This is concordant with other studies, such as a population-based study conducted in the Mediterranean area, which reported NAFLD prevalence measured using ultrasound of 36.8% for men and 25.7% for women. 14 In the multiethnic Dallas Heart Study, a total prevalence of NAFLD of 31%, assessed using MR spectroscopy, was reported. 46 The high prevalence of NAFLD and other cardiometabolic risk factors found in our subsample and elsewhere suggest that the hepatic ultrasound score, based on B-mode ultrasound deepbeam attenuation and the anteroposterior diameter of the right hepatic lobe, may have clinical significance in the context of NAFLD studies, given its good sensitivity, specificity and applicability for population screening purposes.
The FLI and HSI are clinical indices for NAFLD screening that have been described in other samples. 25, 37 In our study, they demonstrated lower performance than our hepatic ultrasound score. Moreover, using one examination as a strategy for screening for NAFLD has the advantage of being more cost-efficient while maintaining sensitivity and specificity and does not require evaluation of additional biomarkers, as suggested by other clinical indices. 25, 37 Our study has limitations, such as the small sample size, which did not have sufficient power to perform ROC analyses across all degrees of hepatic steatosis (mild, moderate and severe). In addition, in this subsample, 64-MDCT was used to assess cross-tabulations of ultrasonography versus a standard imaging technique, because hepatic biopsy would not be feasible due to ethical constraints.
Finally, considering the statistical data obtained, it is probable that the hepatic ultrasound score, based on B-mode ultrasound deep-beam attenuation and the anteroposterior diameter of the right hepatic lobe, will be applicable in the context of NAFLD studies, as previously reported in the literature with regard to the importance of assessing hepatic steatosis using noninvasive methods. 47, 48 Meanwhile, following these preliminary results, we intend to apply this hepatic scoring system to the entire ELSABrasil cohort, which is composed of 15,105 participants.
